MAPT and Cognitive impairment: Furthermore, in a cohort of cognitively unimpaired individuals and individuals with mild cognitive impairment, it was found that cerebrospinal fluid (CSF) phosphorylated tau (p-tau)/Aβ42 (amyloid β 42) ratios (proxy-markers of AD pathology) were associated with neuropsychiatric symptoms [9].